←
Ian Setliff249 posts
Ian Setliff avatar

Ian Setliff

@IanSetliff

Antibodies, Immunology, Protein Engineering, Comp Bio. @urichmond, @VanderbiltU and @Regeneron alum. Views mine.

◷ Joined July 2015
Ivelin Georgiev, Ph.D. avatar
⟳ Ian Setliff retweeted
Ivelin Georgiev, Ph.D.@IG_lab·23 Mar 2022

High-throughput discovery of #epitope-specific #antibodies? There's a #LIBRAseq for that. Great collaborative effort led by @LaurenW_Science. High-Throughput B Cell Epitope Determination by Next-Generation Sequencing frontiersin.org/article/10.3…

Ivelin Georgiev, Ph.D. avatar
⟳ Ian Setliff retweeted
Ivelin Georgiev, Ph.D.@IG_lab·3 Mar 2022

#LIBRAseq with ligand blocking enables targeted discovery of functional (not just binding) #antibodies. Double #ACE2-blockers for both #SARSCoV2 and #SARSCoV were also identified. Easily generalizable for #mAb discovery aiming to block other types of antigen-ligand interactions

Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking go.nature.com/35O9Ali

Post attachment
Ivelin Georgiev, Ph.D. avatar
⟳ Ian Setliff retweeted
Ivelin Georgiev, Ph.D.@IG_lab·18 Sep 2021

Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition cell.com/cell-reports/fullte…

Regeneron avatar
⟳ Ian Setliff retweeted
Regeneron@Regeneron·12 Apr 2021

More #COVID19 News: Positive results from a Phase 3 trial in recently infected asymptomatic patients demonstrate the ability of our investigational antibody cocktail to reduce progression to symptomatic #COVID19. Learn more: https://t.co/rziZOWmcVi

Regeneron avatar
⟳ Ian Setliff retweeted
Regeneron@Regeneron·15 Mar 2021

Announcing our Phase 3 trial in advanced #CervicalCancer was stopped early after achieving its primary efficacy endpoint. Today’s milestone is a “first” for the cervical cancer community. Learn why: https://t.co/ePL40tmYfR CC: @Sanofi

Post attachment
Regeneron avatar
⟳ Ian Setliff retweeted
Regeneron@Regeneron·4 Mar 2021

Today, the FDA accepted for review our sBLA for a treatment for children aged 6 to 11 years with moderate-to-severe #asthma. Learn more: https://t.co/9udThffNN0 @sanofi

Post attachment
Regeneron avatar
⟳ Ian Setliff retweeted
Regeneron@Regeneron·27 Feb 2021

We announced new data on our investigational medicine for patients with #cat allergy and mild asthma at #AAAAI21. Learn more: https://t.co/vKZlP3MqWo

Post attachment
Regeneron avatar
⟳ Ian Setliff retweeted
Regeneron@Regeneron·11 Feb 2021

Today the FDA approved a first-of-its-kind treatment for people with #HoFH, an ultra #rare inherited form of high cholesterol. Read the full announcement: https://t.co/C7ojzpAH8v

Post attachment
Regeneron avatar
⟳ Ian Setliff retweeted
Regeneron@Regeneron·22 Nov 2020

The FDA has issued an Emergency Use Authorization for our investigational antibody cocktail to treat mild to moderate #COVID19 in certain high-risk patients 12 years and older. Learn more: https://t.co/yNfOFPyLI0

Post attachment